123 related articles for article (PubMed ID: 4038368)
1. Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology.
Tiefenbrunn AJ; Robinson AK; Kurnik PB; Ludbrook PA; Sobel BE
Circulation; 1985 Jan; 71(1):110-6. PubMed ID: 4038368
[TBL] [Abstract][Full Text] [Related]
2. Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
Gold HK; Fallon JT; Yasuda T; Leinbach RC; Khaw BA; Newell JB; Guerrero JL; Vislosky FM; Hoyng CF; Grossbard E
Circulation; 1984 Oct; 70(4):700-7. PubMed ID: 6541103
[TBL] [Abstract][Full Text] [Related]
3. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
Collen D; Bounameaux H; De Cock F; Lijnen HR; Verstraete M
Circulation; 1986 Mar; 73(3):511-7. PubMed ID: 2419009
[TBL] [Abstract][Full Text] [Related]
4. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
Van de Werf F; Vanhaecke J; de Geest H; Verstraete M; Collen D
Circulation; 1986 Nov; 74(5):1066-70. PubMed ID: 2429783
[TBL] [Abstract][Full Text] [Related]
5. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
Chen LY; Nichols WW; Saldeen TG; Mehta JL
J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans.
Verstraete M; Bounameaux H; de Cock F; Van de Werf F; Collen D
J Pharmacol Exp Ther; 1985 Nov; 235(2):506-12. PubMed ID: 4057083
[TBL] [Abstract][Full Text] [Related]
7. [Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human].
Seifried E; Böck F; Tanswell P; Rijken DC; Kluft C; Heimpel H
Klin Wochenschr; 1988; 66 Suppl 12():40-9. PubMed ID: 2450222
[TBL] [Abstract][Full Text] [Related]
8. Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction.
Stangl K; Laule M; Tenckhoff B; Stangl V; Gliech V; Dübel P; Grohmann A; Melzer C; Langel J; Wernecke KD; Baumann G; Ziemer S
Am J Cardiol; 1998 Apr; 81(7):841-7. PubMed ID: 9555772
[TBL] [Abstract][Full Text] [Related]
9. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.
Agnelli G; Iorio A; Parise P; Goldhaber SZ; Levine MN
Blood Coagul Fibrinolysis; 1997 Jun; 8(4):216-22. PubMed ID: 9199818
[TBL] [Abstract][Full Text] [Related]
10. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction.
Koster RW; Cohen AF; Hopkins GR; Beier H; Günzler WA; van der Wouw PA
Thromb Haemost; 1994 Nov; 72(5):740-4. PubMed ID: 7534946
[TBL] [Abstract][Full Text] [Related]
12. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
Lucore CL; Fujii S; Sobel BE
Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
[TBL] [Abstract][Full Text] [Related]
13. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Collen D; Van de Werf F
Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis.
Garabedian HD; Gold HK; Leinbach RC; Yasuda T; Johns JA; Collen D
Am J Cardiol; 1986 Oct; 58(9):673-9. PubMed ID: 3094354
[TBL] [Abstract][Full Text] [Related]
15. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
Lucore CL; Sobel BE
Circulation; 1988 Mar; 77(3):660-9. PubMed ID: 2449299
[TBL] [Abstract][Full Text] [Related]
16. Alterations in the fibrinolytic system components during acute myocardial infarction.
Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I
Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123
[TBL] [Abstract][Full Text] [Related]
17. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
18. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.
Mueller HS; Rao AK; Forman SA
J Am Coll Cardiol; 1987 Sep; 10(3):479-90. PubMed ID: 3114349
[TBL] [Abstract][Full Text] [Related]
19. Serial thrombolysis-related changes after thrombolytic therapy with TPA in patients with acute myocardial infarction.
Ho CH; Wang SP
Thromb Res; 1990 May; 58(3):331-41. PubMed ID: 1693793
[TBL] [Abstract][Full Text] [Related]
20. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
